Clover Health Investments

CLOV · NASDAQ

$4.80+$0.36 (+8.11%)TodayMarket closed · Oct 20, 7:55 PM ET

Prev close $4.44

CLOV analyst rating

HoldConsensus of 3 analysts over the last 12 months. 33% rate it a buy.

Strong buy0
Buy1
Hold2
Underperform0
Sell0

12-month price target · 7 analysts

Average $4.74 (−1.2% downside)

Low: $1.77
Now: $4.80
High: $6.30

Upgrades and downgrades

The latest rating actions, newest first

CLOV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Aug 6, 2026	Maintains	Neutral	$4.75 → $5.00	60%
Canaccord Genuity	Jul 21, 2026	Maintains	Buy	$4.20 → $5.50	43%
UBS	Jun 11, 2026	Maintains	Neutral	$2.75 → $4.75	60%
Canaccord Genuity	Jun 4, 2026	Maintains	Buy	$3.20 → $4.20	43%
Canaccord Genuity	Mar 20, 2026	Maintains	Buy	$3.70 → $3.20	43%
Leerink Partners	Mar 5, 2026	Maintains	Market Perform	$3.00 → $2.50	55%
Canaccord Genuity	Jan 20, 2026	Maintains	Buy	$3.70	43%
Canaccord Genuity	Nov 6, 2025	Maintains	Buy	$4.10 → $3.70	43%

The case for and against

Updated Aug 25, 2026

Bull case

Clover Health Investments is poised to continue its strong performance in the coming years, thanks to its innovative software platform, Clover Assistant, which has shown its ability to effectively manage chronic diseases and contain medical costs. With strong retention rates and growth focused on markets where CA has been widely adopted, the company is well positioned to profitably absorb new members and continue improving its unit economics. While there may be some headwinds in 2027 due to a potential downgrade to a 3.5-star plan and flat CMS advance rates, management remains confident that their focus on technology and improving care outcomes will drive profitability. Overall, Clover Health Investments' unique approach to healthcare and strong financial performance make it a promising investment opportunity.

Bear case

Clover Health Investments is a healthcare technology company with a proprietary software platform aimed at managing chronic diseases. While the company achieved profitability in 2025, future headwinds such as a potential decrease in star ratings and flat payment rates in 2027 present risks to future profitability. Additionally, the Clover Assistant platform is facing competition in the marketplace and any regulatory changes to Medicare Advantage could negatively impact the company's financial outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.